Brand name: Tabrecta
Capmatinib hydrochloride is to treat the following conditions:
- Non-small cell lung cancer with a specific MET gene mutation.
- It is also for people who have a metastatic illness.
The FDA’s Accelerated Approval Program has authorized its usage because confirmatory trials prove that capmatinib hydrochloride offers a therapeutic benefit in these individuals.
Research is going on for capmatinib hydrochloride use in the treatment of various cancers.
Capmatinib hydrochloride is an orally accessible inhibitor of the proto-oncogene c-Met (also popular as hepatocyte growth factor receptor (HGFR)) with anticancer potential. Capmatinib binds to c-Met in a specific manner, blocking c-Met phosphorylation and altering c-Met signaling pathways. In tumor cells that overexpress c-Met protein or express the constitutively active c-Met protein, this might lead to cell death. c-Met, a receptor tyrosine kinase that is overexpressed or altered in a variety of tumor cell types, is involved in tumor cell proliferation, survival, invasion, metastasis, and angiogenesis.
Capmatinib Hydrochloride – MedlinePlus Information
A summary of key facts regarding this medication in layman’s terms, which may contain the following:
- Cautions about this medicine
- what is the use and how?
- Whom should you consult before taking it
- what you should know about it before using it
- other drugs that might interact with it
- possible negative effects
Drugs are frequently under research to see whether they can assist treat or prevent conditions other than for which they have been effective. This patient information leaflet only covers uses which have already undergone authorization.
. Much of the material, though, might also apply to authorized uses that are being investigated.